Primary esophageal melanoma

Primary esophageal melanoma is an exceptionally rare malignant neoplasm arising from the esophageal mucosa and belonging to the spectrum of mucosal melanomas. Unlike cutaneous melanoma, which is largely linked to ultraviolet-radiation mutagenesis, esophageal melanoma develops in a mucosal microenvironment with different biological determinants and an histogenetic basis related to the variable and inconsistent presence of melanocytic cells or melanocytosis within the squamous mucosa. The rarity of the entity, its morphologic heterogeneity and the need to methodically exclude an extraesophageal primary site make assessment complex and often delayed, with direct consequences for prognosis and treatment choices.

Clinically, primary esophageal melanoma tends to present with symptoms caused by endoluminal growth and ulceration, particularly dysphagia, weight loss, retrosternal pain, anemia and occult bleeding, producing clinical pictures that may mimic the more common epithelial neoplasms of the esophagus. Diagnosis is based on endoscopy with multiple biopsies and detailed pathologic characterization; immunohistochemistry is central to confirming melanocytic differentiation and distinguishing the tumor from poorly differentiated carcinoma, sarcoma, lymphoma and neuroendocrine neoplasms. Once histologic confirmation has been obtained, extensive clinical and instrumental assessment is essential to exclude a cutaneous, ocular or other mucosal primary site because, in many clinical settings, esophageal metastasis from melanoma is overall more plausible than a primary esophageal form.

Treatment requires a multimodal approach centered, whenever possible, on complete resection and systemic therapy according to the principles used for advanced melanoma and mucosal melanomas. Anti-PD-1 immunotherapy has an important role, as do combinations with anti-CTLA-4 in selected cases or molecularly targeted therapies when actionable alterations, particularly KIT, are present. The clinical course is often aggressive, with a high risk of recurrence and metastasis, making management of local complications, nutritional stabilization and structured follow-up crucial.

The epidemiology of primary esophageal melanoma is dominated by its extreme rarity, and knowledge derives mainly from case reviews, single-center retrospective series and selected multicenter cohorts. The disease represents a very small proportion of esophageal neoplasms and is one of the least frequent sites within the spectrum of mucosal melanomas. This makes precise estimation of incidence and prevalence difficult and requires rigorous diagnostic verification in every case because the differential diagnosis with esophageal metastasis from cutaneous or ocular melanoma is mandatory.

Demographically, the disease primarily affects adults and older people, with a male predominance reported in several series and a tendency to occur in the middle and distal esophagus. The classic endoscopic appearance is a polypoid or lobulated lesion that may be pigmented, but a substantial proportion of tumors are amelanotic, increasing the risk of interpretation as undifferentiated carcinoma or another non-epithelial neoplasm. The combination of endoluminal growth and ulceration explains the frequency of dysphagia and anemia as presenting symptoms.

The etiologic causes of primary esophageal melanoma are unknown, and no exposure has been shown to be necessary and sufficient to cause the disease. In the absence of a defined etiology, attention focuses on plausible or associative risk factors, supported by limited evidence. Unlike cutaneous melanoma, ultraviolet-radiation factors are not relevant; oncogenesis in mucosal melanomas more often appears to be driven by genomic structural alterations and molecular drivers that differ from those of cutaneous forms.

Among factors sometimes discussed, esophageal melanocytosis or intraepithelial melanocytic components adjacent to the tumor have been interpreted as a possible biological substrate or sign of predisposing mucosal melanocytic differentiation, although no causal relationship has been demonstrated. Chronic inflammation and irritant exposures typical of other esophageal diseases also lack solid evidence as specific determinants of melanoma. In summary, the rarity of the entity and absence of a defined risk profile preclude targeted preventive strategies, making diagnosis primarily dependent on recognition of symptoms and the appropriateness of the endoscopic and histologic work-up.

There are no screening programs or population-surveillance protocols for primary esophageal melanoma, mainly because of the exceptional rarity of the disease and the absence of noninvasive tests with adequate diagnostic performance. Even when endoscopy is used for other indications, a dedicated early-detection strategy for this entity cannot be justified because the clinical yield would be negligible and the risk-benefit ratio unfavorable.

In clinical practice, detection occurs through symptom-guided diagnosis. Progressive dysphagia, odynophagia, unintentional weight loss, unexplained iron-deficiency anemia, melena or persistent retrosternal pain require appropriate endoscopic assessment. In these situations, endoscopy is not performed to screen for melanoma but as a necessary investigation for suspected organic esophageal disease, which may unexpectedly lead to a diagnosis of melanoma.

A separate issue concerns patients with known cutaneous or ocular melanoma. In these cases, surveillance is not directed at the development of primary esophageal melanoma but at systemic progression according to melanoma oncology protocols. New esophageal symptoms should be evaluated promptly because metastatic gastrointestinal involvement may present with occult bleeding, anemia or obstructive symptoms.

Overall, the most rational approach remains timely use of endoscopy and biopsy for alarm features, whereas systematic surveillance is neither sustainable nor supported by evidence.

The biology of primary esophageal melanoma reflects the characteristics of mucosal melanomas, which differ from cutaneous melanoma in their mutational patterns, genomic drivers and clinical behavior. A relevant pathogenetic premise is the possible presence of melanocytic cells or melanocytosis in the esophageal squamous mucosa, with malignant transformation promoted by the accumulation of genomic alterations and interaction with the epithelial and stromal microenvironment. In this setting, biological progression is often rapid, with early invasion and lymphatic and hematogenous metastasis.

Compared with cutaneous melanoma, mucosal melanomas generally show a low mutational burden related to the absence of a UV signature and a higher frequency of structural alterations, copy-number changes and rearrangements. This profile contributes to an often aggressive natural history and treatment sensitivity that may differ from cutaneous disease, although selected subgroups retain clinically meaningful responses to immunotherapy.

At the molecular level, MAPK and PI3K pathway dysregulation may occur through drivers different from those in cutaneous melanoma. KIT alterations are particularly relevant in mucosal melanomas and, when present, may constitute a therapeutic target. Alterations in genes involved in cell-cycle control, telomere maintenance and transcriptional regulation have also been described, defining a complexity that makes genomic characterization useful in advanced cases, particularly for therapeutic and prognostic purposes.

Principal biological characteristics of mucosal melanomas relevant to the esophageal site

• Higher frequency of structural and copy-number alterations than in cutaneous melanoma.
• Relatively greater representation of KIT alterations, with potential therapeutic implications in selected cases.
• Possible NRAS mutations and NF1 alterations, whereas BRAF V600 mutations are less frequent on average than in cutaneous melanoma.
• Phenotypic plasticity and microenvironmental adaptation promoting invasiveness, immune escape and treatment resistance.

The mucosal tumor microenvironment may support progression through local immunosuppression, angiogenesis and extracellular-matrix remodeling. The immune infiltrate may show signs of functional exhaustion; assessment of immunologic biomarkers, when appropriate, is mainly relevant in advanced disease and systemic treatment planning, although it is not specific to esophageal melanoma.

Histologically, esophageal melanoma may have epithelioid, spindle-cell or mixed patterns, with marked atypia, frequent mitoses and variable pigmentation. A significant proportion is amelanotic, with morphology mimicking poorly differentiated carcinoma, sarcoma or lymphoma. Demonstration of an in situ component or melanocytic junctional activity in the adjacent epithelium, when documented, supports a mucosal primary origin, although confirmation remains integrated and clinicopathologic.

Typical immunophenotype supporting diagnosis

• Expression of S100 and SOX10 as sensitive markers of melanocytic lineage.
• Frequent positivity for HMB45 and Melan-A, useful for confirming melanocytic differentiation.
• Absence of epithelial markers (cytokeratins) and targeted use of additional panels to exclude carcinoma, GIST, lymphoma or neuroendocrine neoplasms.

Overall, primary esophageal melanoma lies at the intersection of a rare tissue of origin, the distinctive biology of mucosal melanomas and microenvironmental interactions that support invasion and metastasis, explaining its frequent diagnosis at an advanced stage and often unfavorable outcome.

The clinical manifestations of primary esophageal melanoma are predominantly nonspecific and overlap with those of many neoplastic and non-neoplastic esophageal disorders. Endoluminal growth, often with polypoid or nodular morphology, tends to cause progressive dysphagia and a sensation of food impaction, while ulceration of the tumor surface may produce occult bleeding and anemia. Presentation may be insidious, with diagnostic delay favored by the common initial attribution of symptoms to reflux disease, dysmotility or other common conditions.

Patients may report weight loss, reduced intake because of fear of eating, retrosternal pain, odynophagia and regurgitation. In some cases, particularly when the mass is large or located in a critical segment, significant obstruction may cause dehydration and rapid deterioration in nutritional status. When bleeding is substantial, symptoms may include marked fatigue and reduced exercise tolerance.

Advanced disease may produce signs of metastasis, including respiratory symptoms from pulmonary involvement, bone pain, hepatomegaly or general deterioration. Presentation with metastases at diagnosis is not uncommon in several series, so systemic assessment should begin early during the initial diagnostic work-up.

Clinical presentations that most frequently lead to endoscopy

• Progressive dysphagia and a sensation of esophageal obstruction.
• Unintentional weight loss and reduced food intake.
• Unexplained iron-deficiency anemia, with or without occult bleeding.
• Persistent retrosternal pain or odynophagia.
• Regurgitation, nausea and rapid worsening of postprandial symptoms.

Physical examination may reveal no specific findings in early stages; advanced disease may cause pallor, signs of malnutrition and, occasionally, lymphadenopathy or findings secondary to metastases. Overall, clinical features do not reliably indicate the histologic subtype, and endoscopic and histologic confirmation remains indispensable.

The diagnostic work-up for primary esophageal melanoma begins with clinical suspicion of organic esophageal disease and proceeds through a sequence aimed, in order, at histologic demonstration of the neoplasm, characterization of melanocytic differentiation and rigorous verification of an esophageal primary origin. Suspicion typically arises in the presence of progressive dysphagia, weight loss, anemia or retrosternal pain, particularly when alarm features coexist or when symptoms lack a functional explanation.

The decisive first-line examination is esophagogastroduodenoscopy, with careful assessment of the mucosa and lesion. Tumors may appear as polypoid, nodular or ulcerated masses; pigmentation, when present, is suggestive but not constant, and amelanotic forms are an important cause of diagnostic error. The endoscopic appearance should therefore guide tissue sampling rather than be considered definitive. It is essential to obtain multiple deep biopsies, including peripheral areas and ulcerated portions, and to repeat sampling when tissue is not representative or interpretation remains uncertain.

Definitive diagnosis is pathologic. Morphology may mimic poorly differentiated carcinoma, sarcoma or lymphoma, making immunohistochemistry central. A melanocytic panel including S100, SOX10, HMB45 and Melan-A documents melanocytic differentiation; epithelial, mesenchymal, lymphoid and neuroendocrine markers are used selectively to exclude the principal alternatives. When present, an in situ component or junctional activity in the adjacent epithelium may strengthen the hypothesis of a mucosal primary origin, although clinical integration is always required.

A crucial step is excluding an esophageal metastasis from cutaneous, ocular or another mucosal melanoma. This requires a detailed history, complete dermatologic examination, inspection of accessible mucosal surfaces and review of any previous pigmented lesions; ophthalmologic assessment is required when indicated to exclude uveal melanoma. Systemic imaging is essential both for staging and for identifying possible alternative primary sites or a pattern of dissemination that would make attribution to a primary esophageal tumor implausible.

Under a rigorous clinical approach, reliable attribution of an esophageal primary requires integration of minimum clinical and pathologic elements that function as essential prerequisites for correct classification:

Essential clinicopathologic elements for attributing an esophageal primary origin

• An endoscopically documented esophageal lesion with adequate tissue sampling.
• Histologic confirmation of melanoma with a consistent melanocytic immunophenotype.
• No clinical evidence of cutaneous or other mucosal melanoma at diagnosis after careful examination.
• Ophthalmologic assessment when indicated to exclude uveal melanoma.
• Systemic imaging to define disease extent and exclude an alternative primary site or disseminated disease incompatible with attribution to a primary esophageal tumor.

For assessment of extent, contrast-enhanced CT of the chest, abdomen and pelvis is the baseline investigation; 18F-FDG PET is often useful in melanoma because of its sensitivity for detecting metastatic sites and guiding biopsy of distant lesions. Endoscopic ultrasonography contributes to assessment of depth of invasion and suspicious regional lymph nodes, with fine-needle sampling when treatment decisions depend on the result. In summary, diagnosis proceeds through endoscopy with multiple biopsies, immunohistochemical confirmation, systematic exclusion of an extraesophageal primary site, and functional and anatomic radiologic staging with early multidisciplinary integration.

Staging of primary esophageal melanoma is challenging because no universally accepted, site-specific staging system exists, and applying the TNM systems for esophageal carcinoma is inappropriate because of substantial differences in biology and spread patterns. In clinical practice, disease extent is therefore described through careful assessment of local invasion, lymph-node involvement and distant metastases using imaging and, when indicated, histologic confirmation of suspicious sites.

In the absence of a dedicated staging system, many series use stratification based on the anatomic distribution of disease, conceptually corresponding to localized, regional and metastatic disease. This framework does not replace an official system but enables clear clinical communication and pragmatic correlation with treatment choices and prognosis.

Practical classification of disease extent in primary esophageal melanoma

• Localized disease: lesion confined to the esophagus, with no evidence of pathologic lymph nodes or distant metastases.
• Regional disease: locoregional lymph-node involvement documented radiologically or histologically, without distant metastases.
• Metastatic disease: visceral, bone or other extra-regional metastases.

Prognosis is overall unfavorable and depends decisively on extent at diagnosis and the possibility of achieving complete locoregional control. The principal prognostic determinants include distant metastases, lymph-node involvement, lesion size and depth of invasion, resection margins and response to systemic therapy. Frequent diagnosis at an advanced stage, together with the aggressive biology of mucosal melanomas, explains the tendency toward early recurrence even after radical treatment in many series.

Molecular biology may influence outcome mainly through treatment options, because actionable alterations, when present, provide additional therapeutic opportunities. Performance status, nutritional status and comorbidities also affect treatment tolerance and consequently overall prognosis. In patients with severe dysphagia and malnutrition, nutritional stabilization has a practical role because it permits access to potentially effective treatments and reduces the risk of treatment interruption.

Treatment of primary esophageal melanoma requires a multimodal approach based on disease extent, resectability and the possibility of integrating surgery, radiotherapy and systemic therapy. Because of the rarity of the entity, strategies derive from evidence for mucosal melanomas and advanced melanoma, adapted to the esophageal setting and to clinical conditions often affected by dysphagia, weight loss and nutritional impairment.

For localized, resectable disease, surgery is the cornerstone of curative-intent treatment. The aim is complete resection with negative margins; in most cases this entails esophagectomy with reconstruction. Endoscopic resection may be considered only in exceptional scenarios involving very superficial disease with favorable technical criteria and after multidisciplinary assessment, given the high biological risk of dissemination. Lymph-node management is relevant because regional involvement is common; the extent of dissection follows esophageal oncologic principles, although no melanoma-specific standard exists.

Systemic therapy is central in unresectable regional or metastatic disease and may also be considered after resection in selected high-risk settings through multidisciplinary decision-making. Anti-PD-1 immunotherapy is one of the main options; in selected, eligible patients, particularly those with aggressive disease, combination with anti-CTLA-4 may be used, balancing the expected benefit against the risk of immune-mediated toxicity. Regimen selection depends on disease burden, rate of progression, performance status and the ability to manage adverse events promptly.

Molecular profiling is essential in advanced disease because some alterations are treatable. KIT alterations may make tyrosine-kinase inhibitors appropriate in selected patients; BRAF V600 mutations, when present, permit use of BRAF and MEK inhibitor combinations according to melanoma principles. BRAF V600 mutations are less frequent on average in mucosal than in cutaneous melanomas, so strategy must be guided by the individual tumor profile.

Treatment objectives and options according to the clinical setting

• Localized disease: complete surgical resection, with case-by-case assessment of systemic therapy according to clinical and biological risk.
• Unresectable regional disease: immunotherapy as the principal strategy, with reassessment for possible conversion to resectability after a significant response.
• Metastatic disease: anti-PD-1 immunotherapy alone or in combination in selected patients, targeted therapies when actionable alterations are present, and symptom-control strategies.
• Nutritional impairment: intensive nutritional support and management of dysphagia to permit continuity of treatment.

Local and supportive management is often decisive. Dysphagia may require selected palliative endoscopic interventions, temporary enteral or parenteral nutrition and pain control. Radiotherapy may have a palliative role for local symptoms or metastases, while early integration of palliative care together with nutritional support improves quality of life and promotes care consistent with realistic goals.

Follow-up and post-treatment surveillance for primary esophageal melanoma must be individualized because no universally standardized dedicated protocols exist and the rarity of the disease limits comparative evidence. In general, surveillance combines clinical assessment, laboratory monitoring focused on anemia and nutritional status, and periodic imaging to detect recurrence or progression.

In patients treated surgically with curative intent, the first few years represent the period of greatest risk. Surveillance includes regular clinical visits focused on recurrent dysphagia, weight loss, signs of malnutrition and symptoms suggestive of recurrence. Nutritional and functional assessment is an integral part of follow-up because the sequelae of esophagectomy and dietary adaptation substantially affect quality of life and tolerance of any subsequent treatments.

Imaging with CT and, when appropriate, 18F-FDG PET is used to detect recurrence and metastases. Endoscopy is reserved for patients with suggestive symptoms or suspected local recurrence and for management of complications such as anastomotic stenosis or bleeding. In patients receiving systemic treatment for advanced disease, follow-up centers on response assessment and timely diagnosis of toxicity, particularly immune-mediated adverse events, with the frequency of evaluations tailored to the regimen and clinical course.

Long-term quality-of-life considerations in primary esophageal melanoma depend on the interaction among surgical sequelae, the effects of systemic therapies and the psychological impact of a rare diagnosis often perceived as particularly threatening. Even when disease control is achieved, persistent eating difficulties, anxiety about recurrence and the need for close follow-up may significantly affect daily life.

After esophagectomy, dietary changes involving small, frequent meals, early satiety, reflux, altered transit and weight fluctuations are common. Functional recovery often requires ongoing dietetic support and targeted rehabilitation, with attention to sarcopenia and frailty. In patients with prolonged preoperative dysphagia or advanced disease, nutritional impairment may persist and require close monitoring of metabolic parameters and deficiencies.

Immunotherapies may leave chronic sequelae in a proportion of patients, particularly when endocrinopathies or other toxicities require replacement therapy and prolonged specialist follow-up. Integrating management of these sequelae into follow-up is essential because they affect energy, physical performance and ability to work.

The psychological burden may be amplified by uncertainty related to disease rarity and the absence of pathways perceived as standard. Psycho-oncologic care, clear communication about the rationale for decisions and multidisciplinary continuity of care reduce stress and promote adaptation and adherence to follow-up. Overall, quality of life requires active management combining oncologic control with nutritional support, functional rehabilitation and care of long-term treatment sequelae.

Complications of primary esophageal melanoma result from local progression, systemic dissemination and the effects of surgical and systemic treatments. Locally, the most important complication is obstructive progression with severe dysphagia, dehydration and malnutrition, potentially requiring artificial nutrition. Tumor ulceration may cause chronic bleeding with anemia or, less commonly, clinically significant hemorrhage. In advanced disease, metastases may cause organ failure and general deterioration associated with cancer cachexia.

Surgical complications depend on the extent of the procedure and the patient's condition, which is often compromised by poor nutritional status. Anastomotic leaks, stenosis, infection, respiratory complications and delayed functional recovery may affect outcomes and require specialist management and intensive nutritional support. Endoscopic procedures carry risks of bleeding and perforation, particularly in friable or ulcerated tissue, and require appropriate indications and dedicated expertise.

• Immune-mediated toxicity from immunotherapy: colitis, hepatitis, endocrinopathies, dermatitis and immune-mediated pneumonitis, requiring early recognition and specialist management.
• Toxicity from molecularly targeted therapies when indicated: cutaneous, gastrointestinal, hepatic and cardiovascular adverse events varying according to the drug.
• Nutritional complications: weight loss, micronutrient deficiencies, sarcopenia and frailty, particularly after major surgery or in the presence of active disease.

Prevention and management of complications are based on close clinical monitoring, early nutritional support, multidisciplinary management of systemic-treatment toxicities and timely integration of palliative care in advanced cases, with the aim of symptom control and continuity of care.